CZ

Connor Zwick

North America, California, United States, San Francisco

Description

Connor Zwick is the CEO and Co-founder at Speak.

Investor Profile

Connor Zwick has backed more than 1 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 0 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biotechnology, Clinical Trials, Health Care.

Stage Focus

  • Series B (100%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Clinical Trials
  • Health Care
  • Medical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Connor Zwick frequently co-invest with?

BV
North America, California, United States, San Francisco
Co-Investments: 1
General Catalyst
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
BoxGroup
North America, New York, United States, New York
Co-Investments: 1
BC
North America, California, United States, San Francisco
Co-Investments: 1

Which angels does Connor Zwick often collaborate with?

DA
North America, California, United States, San Francisco
Shared Deals: 1
PH
North America, Massachusetts, United States, Cambridge
Shared Deals: 1
JS
North America, Massachusetts, United States, Boston
Shared Deals: 1
TN
North America, California, United States, San Francisco
Shared Deals: 1
GW
North America, California, United States, San Francisco
Shared Deals: 1
NK
North America, New York, United States, New York
Shared Deals: 1
JB
North America, California, United States, San Francisco
Shared Deals: 1
SL
North America, California, United States, San Francisco
Shared Deals: 1

What are some of recent deals done by Connor Zwick?

Vial

San Francisco, California, United States

Scalable biotech advancing clinical programs with cost-effective trials and computationally designed therapeutics.

BiotechnologyClinical TrialsHealth CareMedical
Series BNov 30, 2022
Amount Raised: $67,000,000